Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
IL-23 inhibitors go head to head in Crohn’s disease
Nature Medicine ( IF 58.7 ) Pub Date : 2024-08-19 , DOI: 10.1038/d41591-024-00062-w Karen O’Leary
Nature Medicine ( IF 58.7 ) Pub Date : 2024-08-19 , DOI: 10.1038/d41591-024-00062-w Karen O’Leary
Risankizumab outperformed ustekinumab for the treatment of moderate to severe Crohn’s disease in patients refractory to anti-TNF therapy.
中文翻译：
IL-23 抑制剂在克罗恩病中正面交锋
Risankizumab 在治疗抗 TNF 治疗难治性中度至重度克罗恩病患者方面优于 ustekinumab。
更新日期：2024-08-19
中文翻译：
IL-23 抑制剂在克罗恩病中正面交锋
Risankizumab 在治疗抗 TNF 治疗难治性中度至重度克罗恩病患者方面优于 ustekinumab。
京公网安备 11010802027423号